Afsaneh further said that taking colorectal cancer as an example, the first 3 years after surgery for patients are at high risk of recurrence, and in the past, the tracking was mainly based on the traditional tumor marker CEA, but the research results showed that the CEA tumor index is prone to false positives or false negatives in interpretation, among which nearly 20% of colorectal cancer patients who smoke produce false positives, while DR-70 is not affected by smoking, and many patients have abnormally high indexes due to factors such as inflammation in the body, and the ups and downs of the index. The joys, sorrows, sorrows and sorrows of patients and their families can cause unnecessary panic among patients and miss the golden treatment period in vain.
Make good use of DR-70 to accurately track colorectal cancer patients to grasp the golden treatment period
▲ Afsaneh pointed out that the new detection technology DR-70 is more sensitive and accurate than traditional tumor markers, and can provide more accurate detection results for medical teams and patients. (Photo/Courtesy of Dr.)
With the advent of summer, the barbecue season will follow, according to the National Health Administration recently announced the top ten cancer rankings, in 2013 there were 99,143 new cancer cases, of which colorectal cancer won the championship for 8 consecutive degrees, and the high rate of colorectal cancer, in addition to the westernization of the diet, is also related to the Chinese people’s love of barbecue and heavy food.
Dr. Afsaneh Motamed-Khorasani, an American cancer research expert, recently attended the Asian Congress of Clinical Pathology and Laboratory Medicine (ASCPaLM 2016) and mentioned that cancer is different from other diseases, it is spread and aggressive, once a part of treatment is neglected, it is often easy to cause delays and take more time and money, so only good screening and prevention are important keys.
Afsaneh further said that taking colorectal cancer as an example, the first 3 years after surgery for patients are at high risk of recurrence, and in the past, the tracking was mainly based on the traditional tumor marker CEA, but the research results showed that the CEA tumor index is prone to false positives or false negatives in interpretation, among which nearly 20% of colorectal cancer patients who smoke produce false positives, while DR-70 is not affected by smoking, and many patients have abnormally high indexes due to factors such as inflammation in the body, and the ups and downs of the index. The joys, sorrows, sorrows and sorrows of patients and their families can cause unnecessary panic among patients and miss the golden treatment period in vain.
In view of this, if the tracking results cannot be properly controlled, it is easy to have a psychological impact on patients and their families. Afsaneh pointed out that the new detection technology DR-70 has higher sensitivity and accuracy than traditional tumor markers, and can detect cancer cells at an early stage of growth, and can effectively detect 71.6% of colorectal cancer patients with normal CEA, which can make up for the lack of sensitivity in the early stage of CEA and provide more accurate detection results for medical teams and patients.
DR-70 has been approved by the US FDA in 2008 for use in colorectal cancer surveillance tumor marker, and is also the only tumor marker approved by the US FDA for colorectal cancer since 1985, and has been adopted by 12 medical centers in Taiwan, which can not only help the medical team effectively control the disease, early detection and early treatment, but also reduce the psychological pressure of patients, increase the willingness to follow up regularly, and stay away from the threat of recurrence.
